How Effective is Ixazomib?

Ixazomib is a proteasome inhibitor drug. Its mechanism of action is to prevent multiple myeloma cells from breaking down proteins, leading to the accumulation of intracellular proteins and subsequent induction of cell death.

How Effective is Ixazomib?

The U.S. Food and Drug Administration (FDA) may grant priority review status (including accelerated review) to drug applications for therapies that treat serious diseases and would demonstrate significant improvements in safety or efficacy over existing treatments if approved. Recently, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment status to ixazomib.

The new drug application for ixazomib is mainly based on the results of the first pre-specified interim analysis of the pivotal Phase III clinical trial TOURMALINE-MM1. This study is an international, multicenter, randomized, double-blind, placebo-controlled clinical trial that enrolled a total of 722 adult patients with relapsed and/or refractory multiple myeloma. It was designed to evaluate the superiority of ixazomib in combination with lenalidomide and dexamethasone, compared with placebo plus lenalidomide and dexamethasone. Patients in the trial received continuous treatment until disease progression, with long-term outcome assessment to be conducted.

Storage Conditions for Ixazomib

1. Keep this product out of the reach of children.

2. Do not retain expired or unused medication.

3. Consult a healthcare professional for instructions on how to dispose of unused drugs.

4. Store the medication in a tightly sealed container at room temperature, away from heat, moisture and direct sunlight. Do not freeze.

5. Keep the medication in its original packaging until use.

Toxic Reactions of Ixazomib

Ixazomib-related toxicities include hematologic toxicity and hepatotoxicity. Hematologic toxicity is mainly manifested as thrombocytopenia, which was most commonly observed within the first 3 months of treatment in the drug’s approval studies. Platelet levels typically decrease after administration and recover before the next treatment cycle. During the study period, a small number of patients required discontinuation of ixazomib treatment due to thrombocytopenia [15]. As mentioned above, ixazomib also carries a risk of hepatotoxicity because patients may develop different types of liver injury; therefore, liver function monitoring is crucial.

In addition, unlike other previously reported proteasome inhibitors that may cause cardiotoxicity, ixazomib has not been found to increase cardiac events, induce cardiotoxicity, or prolong the QTc interval. Compared with bortezomib, ixazomib has lower neurotoxicity; relative to carfilzomib, it has reduced cardiotoxicity.